Survivin DNA vaccine generated specific antitumor effects in pancreatic carcinoma and lymphoma mouse models (Q40068596)

17 September 2017

Survivin DNA vaccine generated specific antitumor effects in pancreatic carcinoma and lymphoma mouse models (English)

1 reference

17 September 2017

1 reference

8

Patrick Hwu

1 reference

17 September 2017

4

Sattva S Neelapu

1 reference

17 September 2017

Kuichun Zhu

1

1 reference

17 September 2017

Hong Qin

2

1 reference

17 September 2017

Soung-Chul Cha

3

1 reference

17 September 2017

Willem Overwijk

5

1 reference

17 September 2017

Gregory A Lizee

6

1 reference

17 September 2017

James L Abbruzzese

7

1 reference

17 September 2017

Laszlo Radvanyi

9

1 reference

17 September 2017

Larry W Kwak

10

1 reference

17 September 2017

David Z Chang

11

1 reference

17 September 2017

language of work or name

English

0 references

publication date

14 September 2007

1 reference

17 September 2017

7

1 reference

based on heuristic

inferred from page(s)

published in

Vaccine

1 reference

17 September 2017

25

1 reference

17 September 2017

46

1 reference

17 September 2017

7955-7961

1 reference

Regulation of apoptosis at cell division by p34cdc2 phosphorylation of survivin

17 September 2017

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.08.050

Survivin' cell-separation anxiety

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.08.050

Expression of survivin, a novel inhibitor of apoptosis and cell cycle regulatory protein, in pancreatic adenocarcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.08.050

Expression of survivin is correlated with cancer cell apoptosis and is involved in the development of human pancreatic duct cell tumors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.08.050

Cancer gene therapy using a survivin mutant adenovirus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.08.050

Expression of Survivin in pancreatic cancer and its correlation to expression of Bcl-2.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.08.050

Survivin expression is a prognostic marker in pancreatic cancer patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.08.050

Downregulation of survivin by siRNA diminishes radioresistance of pancreatic cancer cells.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.08.050

A role for survivin in radioresistance of pancreatic cancer cells.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.08.050

A potent immunogenic general cancer vaccine that targets survivin, an inhibitor of apoptosis proteins.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.08.050

Generation of cytotoxic responses in mice and human individuals against hematological malignancies using survivin-RNA-transfected dendritic cells.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.08.050

Antitumor effects of a xenogeneic survivin bone marrow derived dendritic cell vaccine against murine GL261 gliomas.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.08.050

DNA-based vaccines activate innate and adaptive antitumor immunity by engaging the NKG2D receptor

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.08.050

Induction of antitumour immunity using survivin peptide-pulsed dendritic cells in a murine lymphoma model.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.08.050

Lack of toxicity of therapy-induced T cell responses against the universal tumour antigen survivin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.08.050

Phase I clinical study of anti-apoptosis protein, survivin-derived peptide vaccine therapy for patients with advanced or recurrent colorectal cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.08.050

Complete remission of liver metastasis of pancreatic cancer under vaccination with a HLA-A2 restricted peptide derived from the universal tumor antigen survivin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.08.050

Genetic immunization of mice with human tyrosinase-related protein 2: implications for the immunotherapy of melanoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.08.050

A single heteroclitic epitope determines cancer immunity after xenogeneic DNA immunization against a tumor differentiation antigen

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.08.050

Immunogene therapy of tumors with vaccine based on xenogeneic epidermal growth factor receptor

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.08.050

A novel model system for studying the double-edged roles of nitric oxide production in pancreatic cancer growth and metastasis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.08.050

Genetic fusion of chemokines to a self tumor antigen induces protective, T-cell dependent antitumor immunity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.08.050

7 January 2021

Cancer statistics, 2005

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.08.050

Gemcitabine in combination with oxaliplatin compared with gemcitabine alone in locally advanced or metastatic pancreatic cancer: results of a GERCOR and GISCAD phase III trial.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.08.050

Optimization of a self antigen for presentation of multiple epitopes in cancer immunity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.08.050

10.1016/J.VACCINE.2007.08.050

7 January 2021

Identifiers

DOI

1 reference

17 September 2017

1 reference